S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-1.16%) $1.619
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

Sanntidsoppdatering for Johnson & Johnson [JNJ.DE]

Børs: XETRA Sektor: Pharmaceuticals Industri: Drug Manufacturers—General
Sist oppdatert26 apr 2024 @ 17:35

0.15% 137.20

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 17:35):

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide...

Stats
Dagens volum 4 839.00
Gjennomsnittsvolum 3 176.00
Markedsverdi 330.62B
EPS €0 ( 2024-04-15 )
Neste inntjeningsdato ( €0 ) 2024-07-16
Last Dividend €1.190 ( 2023-08-25 )
Next Dividend €0 ( N/A )
P/E 19.74
ATR14 €0.125 (0.09%)

Volum Korrelasjon

Lang: -0.05 (neutral)
Kort: -0.75 (moderate negative)
Signal:(64.235) Neutral

Johnson & Johnson Korrelasjon

10 Mest positive korrelasjoner
10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Johnson & Johnson Korrelasjon - Valuta/Råvare

The country flag 0.51
( weak )
The country flag 0.61
( weak )
The country flag 0.00
( neutral )
The country flag 0.35
( neutral )
The country flag -0.05
( neutral )
The country flag -0.65
( weak negative )

Johnson & Johnson Økonomi

Annual 2023
Omsetning: €85.16B
Bruttogevinst: €58.61B (68.82 %)
EPS: €13.88
FY 2023
Omsetning: €85.16B
Bruttogevinst: €58.61B (68.82 %)
EPS: €13.88
FY 2022
Omsetning: €94.94B
Bruttogevinst: €63.85B (67.26 %)
EPS: €6.86
FY 2021
Omsetning: €93.78B
Bruttogevinst: €63.92B (68.16 %)
EPS: €7.93

Financial Reports:

No articles found.

Johnson & Johnson Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
€1.130
(N/A)
€1.130
(N/A)
€1.130
(N/A)
€1.190
(N/A)
€1.190
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)

Johnson & Johnson Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 3.76 - low (25.10%) | Divividend Growth Potential Score: 5.82 - Stable (16.47%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend €0.415 2008-02-22
Last Dividend €1.190 2023-08-25
Next Dividend €0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 65 --
Total Paid Out €56.18 --
Avg. Dividend % Per Year 0.00% --
Score 3.59 --
Div. Sustainability Score 3.76
Div.Growth Potential Score 5.82
Div. Directional Score 4.79 --
Next Divdend (Est)
(2024-07-01)
€1.211 Estimate 22.50 %
Dividend Stability
0.60 Above Average
Dividend Score
3.59
Pay Frequency
Quarterly
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for XETRA

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
RIO1.DE Ex Dividend Knight 2023-08-10 Semi-Annually 0 0.00%
BST.DE Ex Dividend Junior 2023-09-14 Sporadic 0 0.00%
JNJ.DE Ex Dividend Knight 2023-08-25 Quarterly 0 0.00%
TA1.DE Ex Dividend Knight 2023-06-12 Annually 0 0.00%
DEF.DE Ex Dividend Knight 2023-07-24 Annually 0 0.00%
MMM.DE Ex Dividend Junior 2023-08-18 Quarterly 0 0.00%
4I1.DE Ex Dividend Knight 2023-09-26 Quarterly 0 0.00%
VVD.DE Ex Dividend Knight 2023-05-09 Annually 0 0.00%
EVK.DE Ex Dividend Junior 2023-06-01 Annually 0 0.00%
OMV.DE Ex Dividend Knight 2023-06-06 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.4531.5000.9491.424[0 - 0.5]
returnOnAssetsTTM01.20000[0 - 0.3]
returnOnEquityTTM0.5721.5004.767.14[0.1 - 1]
payoutRatioTTM0.218-1.0007.82-7.82[0 - 1]
currentRatioTTM00.800-5.00-4.00[1 - 3]
quickRatioTTM00.800-4.71-3.76[0.8 - 2.5]
cashRatioTTM01.500-1.111-1.667[0.2 - 2]
debtRatioTTM0-1.50000[0 - 0.6]
interestCoverageTTM44.511.00010.0010.00[3 - 30]
operatingCashFlowPerShareTTM8.032.007.3210.00[0 - 30]
freeCashFlowPerShareTTM6.322.006.8410.00[0 - 20]
debtEquityRatioTTM0-1.50000[0 - 2.5]
grossProfitMarginTTM0.6871.0001.8901.890[0.2 - 0.8]
operatingProfitMarginTTM0.2731.0006.546.54[0.1 - 0.6]
cashFlowToDebtRatioTTM01.000-1.111-1.111[0.2 - 2]
assetTurnoverTTM00.800-3.33-2.67[0.5 - 2]
Total Score3.76

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM8.801.0009.210[1 - 100]
returnOnEquityTTM0.5722.506.637.14[0.1 - 1.5]
freeCashFlowPerShareTTM6.322.007.8910.00[0 - 30]
dividendYielPercentageTTM3.241.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM8.032.007.3210.00[0 - 30]
payoutRatioTTM0.2181.5007.82-7.82[0 - 1]
pegRatioTTM-0.3031.500-5.350[0.5 - 2]
operatingCashFlowSalesRatioTTM0.2181.0007.050[0.1 - 0.5]
Total Score5.82

Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Om Live Signaler

Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.

Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.